Adjuvant Immunochemotherapy with Protein-Bound Polysaccharide K for Colon Cancer in Relation to Oncogenic β-Catenin Activation

Due to a production error, uncorrected versions of Figure 1, Table 1, Table 2, Table 5, and Supplementary Tables 1 and 2 were included in the article published in this issue (DOI: 10.1007/s10350-006-0842-5). We reprint them here in their entirety on the following pages. In addition, line 3 of the first paragraph in the section “Statistical Analysis of the Data and Survival Rates” should read “chi-square test” not “chi-squared test.”

Figure 1

Representative expression patterns of β-catenin (A–C) and the active subunit (p65) of nuclear factor-kappaB (NF-κB) (D) in colon cancer. A. Membranous expression. B. Diffuse nuclear accumulation-type β-catenin activation. C. Nuclear accumulation in the tumor invasion front-type β-catenin activation. D. Expression of the p65 subunit of NF-κB in tumor cells’ nuclei. Bar in each panel indicates a length of 100 μM.

Table 1 Comparison of Clinicopathologic Characteristics and Survival Rate Between the Groups of Patients with Regard to Different Forms of Adjuvant Therapy and Different Status of β-catenin Activation in the Primary Tumor

Table 2 Comparison of Survival Rates in Patients with NAd-type β-catenin Activation

Table 5 Influences of the Clinical and Histopathologic Characteristics and Types of Adjuvant Therapy on Survival of Patients with NAd-type β-catenin Activation in the Primary Tumor

Supplementary Table 1 Comparison of Clinicopathologic Characteristics and Survival Rates Between the Original Cohort of Patients in CIP Study and the Cohort of the Present Study

Supplementary Table 2 Comparison of Clinicopathologic Characteristics, Treatment Options, and β-catenin and NF-κB Activation in the Tumor in the Respective Groups of Patients with Colon Cancer

Springer regrets the error.